Extension of escuddo follow-up from five years to 7.5 years (referred to as escuddo-7) will evaluate the durability of the non-inferiority of protection afforded by one versus two doses of the HPV…
Active Awarded Last action
- Contract number
- 75N91025F00001
- Awardee
-
Fundacion Inciensa UEI KDL2VERNRKA5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $9,770,641
Award facts
- Contract value 70% obligated
-
- $9,770,641.00 Current, with exercised options
- $14,016,447.00 Potential, with all options
- Completion date 64% complete
- Current and potential, with all options
- NAICS code
- 541720 Research and Development in the Social Sciences and Humanities
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Costa Rica
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Change Order | $213,695 | |
| Exercise an Option | $6,003,058 | |
| Original award | $3,553,888 |
About this award
The National Cancer Institute issued a delivery order to Fundacion Inciensa on March 26, 2025, with a ceiling value of $14,016,447 under the organization's single-award Indefinite Delivery Contract for epidemiology and infectious disease research services. The order funds the ESCUDDO-7 long-term follow-up study, which extends the ESCUDDO HPV vaccine durability trial from five years to 7.5 years to evaluate non-inferiority of protection afforded by one versus two doses of HPV vaccines.
Place of performance is Costa Rica. Work is scheduled for completion by September 15, 2027. In fiscal year 2025, Fundacion Inciensa invoiced $3.6 million against this order with 40.3 FTEs, performing all work in-house with no reported subcontractors.
Description
Extension of escuddo follow-up from five years to 7.5 years (referred to as escuddo-7) will evaluate the durability of the non-inferiority of protection afforded by one versus two doses of the HPV vaccines.
Quick answers
Who was awarded contract 75N91025F00001?
75N91025F00001 was awarded to Fundacion Inciensa by National Cancer Institute (National Institutes of Health) on March 26, 2025.
How much is contract 75N91025F00001 worth?
The government has obligated $9,770,641 on 75N91025F00001. Its potential value, with all options, is $14,016,447.
Is contract 75N91025F00001 an order under another contract?
Yes. 75N91025F00001 is a delivery order under 75N91024D00014, an indefinite delivery contract.
Was contract 75N91025F00001 competed?
The extent of competition for 75N91025F00001 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award